Naason Science CRO (Contract Research Organization) - Where the next generation of preclinical research begins!Faster, better decisions - Based on knowledge of drug discovery and outsourcing experience, building the best integrated global preclinical services with an emphasis on innovation, reliability and commitment. Naason´s various preclinical modelling platforms are customized to suite the needs of drug developers. The platforms can accommodate all drug delivery routes as well as preclinical proof-of-concept for medical devices. From in vitro systems to large and small animal in vivo models Naason Science provides a tool box of state-of-the-art technologies the allow for rapid and effective testing of preclinical drug candidates. The Naason process starts from an in-depth knowledge of the demands of global pharmaceutical development. It involves combining superior knowledge of biological systems and system dynamics with the latest preclinical disease models, highlighting the comparative and translatable aspects and using this data to highlight the way forward for a particular drug or a drug development platform. The data generated from our preclinical modelling platforms is designed to provide pertinent insight and better translatability in order to allow for easier decisions made faster. Faster decision making allows a reduction in the cost of research and development. Naason Science provides the tools to study neurology, oncology, cardiovascular and metabolic therapies in a way that allows faster and better decisions. Let us show you !
DMD, SCA, BattenPsychiatry >>>
Schizophrenia, Depression, AnxietyPain >>>
Neuropathic-Chung, CCI, Visceral-Endometriosis, Bladder, Chemotherapy-induced pain, Central PainOncology >>>
Syngenic Melanoma, Xenograph, Pancreatic Cancer, GlioblastomaCardiology >>>
Ischemia, Hemostats in rodents & pigs
Metabolic diseases >>>
NASH, DiabetesSafety & Toxicology >>>
Mouse, rat, canine, pig, NHP, ADME PK
BACHD rat line is Huntington’s Disease transgenic rat model using human bacterial artificial chromosome (BAC) which contains the full-length HTT genomic sequence with 97 CAG/CAA repeats. BACHD rats display a robust, early-onset and progressive HD-like phenotype including motor deficits and anxiety-related symptoms. The phenotype is characterized by striatal dysfunction, followed by progressive brain volume reduction starting in the striatum. Neuropathologically, the distribution of neuropil aggregates and nuclear accumulations of N-terminal mutant huntingtin in BACHD rats is similar to that seen in HD patients.
Most viewed models
150+ Years of Cumulative CRO and Preclinical Drug Development Experience
located in two world class cutting-edge centers of Osong Bio-medical Science Complex in Osong and DGMIF in Daegu, South Korea.
Copyright © Naason Science Inc 2019. All rights reserved.